Next Article in Journal
Macrophages and Phospholipases at the Intersection between Inflammation and the Pathogenesis of HIV-1 Infection
Next Article in Special Issue
Obesity and Asthma: A Missing Link
Previous Article in Journal
Dry Eye Management: Targeting the Ocular Surface Microenvironment
Previous Article in Special Issue
Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction

Adipokines in Liver Cirrhosis

Department of Internal Medicine I, University Hospital Regensburg, 93042 Regensburg, Germany
Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, 93042 Regensburg, Germany
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(7), 1392;
Received: 30 May 2017 / Revised: 23 June 2017 / Accepted: 27 June 2017 / Published: 29 June 2017
(This article belongs to the Special Issue Adipokines)
Liver fibrosis can progress to cirrhosis, which is considered a serious disease. The Child-Pugh score and the model of end-stage liver disease score have been established to assess residual liver function in patients with liver cirrhosis. The development of portal hypertension contributes to ascites, variceal bleeding and further complications in these patients. A transjugular intrahepatic portosystemic shunt (TIPS) is used to lower portal pressure, which represents a major improvement in the treatment of patients. Adipokines are proteins released from adipose tissue and modulate hepatic fibrogenesis. These proteins affect various biological processes that are involved in liver function, including angiogenesis, vasodilation, inflammation and deposition of extracellular matrix proteins. The best studied adipokines are adiponectin and leptin. Adiponectin protects against hepatic inflammation and fibrogenesis, and leptin functions as a profibrogenic factor. These and other adipokines are supposed to modulate disease severity in patients with liver cirrhosis. Consequently, circulating levels of these proteins have been analyzed to identify associations with parameters of hepatic function, portal hypertension and its associated complications in patients with liver cirrhosis. This review article briefly addresses the role of adipokines in hepatitis and liver fibrosis. Here, studies having analyzed these proteins in systemic blood in cirrhotic patients are listed to identify adipokines that are comparably changed in the different cohorts of patients with liver cirrhosis. Some studies measured these proteins in systemic, hepatic and portal vein blood or after TIPS to specify the tissues contributing to circulating levels of these proteins and the effect of portal hypertension, respectively. View Full-Text
Keywords: adiponectin; leptin; MELD; ascites; portal vein adiponectin; leptin; MELD; ascites; portal vein
Show Figures

Graphical abstract

MDPI and ACS Style

Buechler, C.; Haberl, E.M.; Rein-Fischboeck, L.; Aslanidis, C. Adipokines in Liver Cirrhosis. Int. J. Mol. Sci. 2017, 18, 1392.

AMA Style

Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in Liver Cirrhosis. International Journal of Molecular Sciences. 2017; 18(7):1392.

Chicago/Turabian Style

Buechler, Christa, Elisabeth M. Haberl, Lisa Rein-Fischboeck, and Charalampos Aslanidis. 2017. "Adipokines in Liver Cirrhosis" International Journal of Molecular Sciences 18, no. 7: 1392.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop